The document discusses exciting developments in medical cannabis education. It summarizes the need for continuing medical education on cannabinoids given their therapeutic potential. The Canadian Consortium for the Investigation of Cannabinoids (CCIC) is highlighted as a non-profit organization providing accredited cannabis education to clinicians to promote evidence-based practice. While funding and changing practitioner attitudes present challenges, the CCIC works to bring credibility to the field through multidisciplinary expert faculty and diverse programming approaches.
This document discusses opportunities for developing medical cannabis-based drugs, including over 100 potential clinical applications. It outlines two major cannabinoids - THC and CBD - and their therapeutic effects. Developing cannabis-based medicines requires navigating regulations as cannabis is currently a Schedule I drug. Preclinical studies must address regulatory concerns and mimic future clinical use. Successful drug development requires collaboration between clinical/regulatory experts, scientists, and those who can secure intellectual property protection and financing.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● An overview of the court case including the main details, the plaintiffs, and what they were seeking,
● Analysis of the evidence presented during the proceedings,
● What the decision means for patients and producers, and
● Things to come for medical marijuana in Canada
View the video: https://youtu.be/n80-7qGiEnU
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
This document discusses opportunities for developing medical cannabis-based drugs, including over 100 potential clinical applications. It outlines two major cannabinoids - THC and CBD - and their therapeutic effects. Developing cannabis-based medicines requires navigating regulations as cannabis is currently a Schedule I drug. Preclinical studies must address regulatory concerns and mimic future clinical use. Successful drug development requires collaboration between clinical/regulatory experts, scientists, and those who can secure intellectual property protection and financing.
Este documento presenta información sobre juegos modificados en educación física. Define el juego modificado como un juego que mantiene los principios tácticos de los deportes estándar pero reduce las exigencias técnicas. Describe dos ejemplos de juegos modificados: "Sillas musicales", donde los jugadores compiten por asientos cuando la música para; y "El enredo", donde los jugadores se unen de las manos y tratan de deshacer el nudo formado.
Throughout history, cannabis has been used as a panacea, an herbal remedy for nearly all medical concerns from simple headaches to severe pain. Now that many states have legalized medical cannabis, it is important to have analytical methodologies to study the compounds that the patients will be ingesting or inhaling. Terpenes are a major class of compounds found in cannabis. They are volatile hydrocarbons responsible for the plant’s aroma. These compounds are found in other plants as well. Through various clinical trials they were found to be medically relevant. In terms of cannabis, these compounds reportedly assist the cannabinoids in their effects. The cannabinoids bind to the cannabinoid receptor in the brain, and thus have medical relevance. Cannabichromene, cannabidiol, cannabigerol, and cannabinol are the main four cannabinoids that are implicated in relieving symptoms of pain, nausea, and directly reducing seizures. Delta-9-tetrahydrocannabinol is responsible for the euphoria experienced when smoked or ingested.
With the increase in usage of cannabis due to its medical legalization in many states, it is important to have analytical methods for testing potency and variance of the cannabinoids and terpenes within the plant material. To do this, terpenes and cannabinoids were analyzed using a GC-FID. As the terpenes have higher volatility, several injection techniques were tested, including liquid injection, SPME, and headspace. The cannabinoid method was then applied to test the variance in subsequent doses of the same size, mimicking that of doses distributed to patients.
International Medical Cannabis Policy - Boaz Watchel (Israel) SafeAccess
Israel has had a medical cannabis program since the 1990s that has expanded significantly. It is now one of the largest in the world, serving over 10,000 patients through licensed producers. The program was initially run through the Ministry of Health but is now managed by a new National Medical Cannabis Agency. This allows for standardized distribution to pharmacies and home delivery. Research on medical cannabis in Israel has shown promising results for reducing symptoms of PTSD and other conditions. The program provides patients access to strains of standardized quality within a regulated framework.
This document discusses opportunities for developing medical cannabis-based drugs, including over 100 potential clinical applications. It outlines two major cannabinoids - THC and CBD - and their therapeutic effects. Developing cannabis-based medicines requires navigating regulations as cannabis is currently a Schedule I drug. Preclinical studies must address regulatory concerns and mimic future clinical use. Successful drug development requires collaboration between clinical/regulatory experts, scientists, and those who can secure intellectual property protection and financing.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● An overview of the court case including the main details, the plaintiffs, and what they were seeking,
● Analysis of the evidence presented during the proceedings,
● What the decision means for patients and producers, and
● Things to come for medical marijuana in Canada
View the video: https://youtu.be/n80-7qGiEnU
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
This document discusses opportunities for developing medical cannabis-based drugs, including over 100 potential clinical applications. It outlines two major cannabinoids - THC and CBD - and their therapeutic effects. Developing cannabis-based medicines requires navigating regulations as cannabis is currently a Schedule I drug. Preclinical studies must address regulatory concerns and mimic future clinical use. Successful drug development requires collaboration between clinical/regulatory experts, scientists, and those who can secure intellectual property protection and financing.
Este documento presenta información sobre juegos modificados en educación física. Define el juego modificado como un juego que mantiene los principios tácticos de los deportes estándar pero reduce las exigencias técnicas. Describe dos ejemplos de juegos modificados: "Sillas musicales", donde los jugadores compiten por asientos cuando la música para; y "El enredo", donde los jugadores se unen de las manos y tratan de deshacer el nudo formado.
Throughout history, cannabis has been used as a panacea, an herbal remedy for nearly all medical concerns from simple headaches to severe pain. Now that many states have legalized medical cannabis, it is important to have analytical methodologies to study the compounds that the patients will be ingesting or inhaling. Terpenes are a major class of compounds found in cannabis. They are volatile hydrocarbons responsible for the plant’s aroma. These compounds are found in other plants as well. Through various clinical trials they were found to be medically relevant. In terms of cannabis, these compounds reportedly assist the cannabinoids in their effects. The cannabinoids bind to the cannabinoid receptor in the brain, and thus have medical relevance. Cannabichromene, cannabidiol, cannabigerol, and cannabinol are the main four cannabinoids that are implicated in relieving symptoms of pain, nausea, and directly reducing seizures. Delta-9-tetrahydrocannabinol is responsible for the euphoria experienced when smoked or ingested.
With the increase in usage of cannabis due to its medical legalization in many states, it is important to have analytical methods for testing potency and variance of the cannabinoids and terpenes within the plant material. To do this, terpenes and cannabinoids were analyzed using a GC-FID. As the terpenes have higher volatility, several injection techniques were tested, including liquid injection, SPME, and headspace. The cannabinoid method was then applied to test the variance in subsequent doses of the same size, mimicking that of doses distributed to patients.
International Medical Cannabis Policy - Boaz Watchel (Israel) SafeAccess
Israel has had a medical cannabis program since the 1990s that has expanded significantly. It is now one of the largest in the world, serving over 10,000 patients through licensed producers. The program was initially run through the Ministry of Health but is now managed by a new National Medical Cannabis Agency. This allows for standardized distribution to pharmacies and home delivery. Research on medical cannabis in Israel has shown promising results for reducing symptoms of PTSD and other conditions. The program provides patients access to strains of standardized quality within a regulated framework.
The document discusses various methods of administering medical cannabis for cancer patients including inhalation, ingestion, and topical application. It notes the time of onset and duration of effects for each method. The document also provides an overview of the endocannabinoid system and how cannabis may help certain cancer symptoms like pain, appetite issues, and nausea. It outlines some promising areas of preclinical research on cannabinoids treating different types of cancer. Potential side effects of cannabis are also mentioned.
Cannabis use is common among those with bipolar disorder. Rates of cannabis abuse are higher among those with bipolar disorder compared to the general population. Cannabis use is associated with increased risk of manic symptoms and can worsen the course of bipolar disorder through increased relapses and hospitalizations. Effective management of comorbid cannabis use and bipolar disorder requires screening, assessment, psychoeducation, and integrated treatment targeting both conditions.
The world is watching as Canada becomes one of the first countries to legalize recreational cannabis, and there's still much we don't know about how this huge social change will affect our lives.
In this webinar, Dr. Chris Wilkes, MD, from UCalgary's Cumming School of Medicine reviews what the research to date tells us about the impact of cannabis on the brain, and what needs further study. Dr. Fiona Clement, PhD, whose team compiled the Cannabis evidence series for the Alberta provincial government, looks at the factors informing government policy, including evidence from other jurisdictions that have legalized marijuana.
Watch the full webinar recording at https://go.ucalgary.ca/2018-07-11URNAP-WhatdoeslegalizedcannabismeanforCanadians_LPRegistration.html
There are countless questions when it comes to medical cannabis and colorectal cancer: How can it help? How do you get it? Are there drug interactions with chemo? What are the side effects? Is it legal where I live?
Cannabidiol (CBD) shows potential as an anti-seizure treatment based on animal studies and anecdotal human reports. CBD appears to reduce seizures independently of CB1 receptors and has a more favorable safety profile than THC in studies. Open-label trials of CBD-enriched cannabis in pediatric epilepsy patients showed reductions in seizure frequency for most participants. However, placebo-controlled studies are still needed to determine CBD's efficacy and safety compared to existing anti-seizure medications.
There are countless questions when it comes to medical cannabis and colorectal cancer: How can it help? How do you get it? Are there drug interactions with chemo? What are the side effects? Is it legal where I live?
The document discusses ongoing debates around the medical use of marijuana. It examines research on marijuana's potential effects on various diseases including cancer, gastrointestinal issues, and mental health conditions. Studies have shown marijuana may help treat cancer by restricting tumor growth and reducing angiogenesis and metastasis. A study on Crohn's disease found patients using marijuana experienced remission of symptoms and improved conditions. However, more research is still needed to fully understand marijuana's medical applications and effects, especially in relation to mental health.
Medical Marijuana and Clinical Oncology in 2022"The Good the Bad and the Potentially Ugly"
Marijuana/cannabinoids are particularly appealing for oncology patients offering the possibility of a single medication to encompass a variety of problems, such as pain, nausea, anorexia, sleep disorders , and anxiety.
Dr. Malcolm Brigden - University of Calgary - Canada.
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
At this webinar you will learn:
• Basic facts about medical cannabis in Canada
• The role of medical cannabis for cancer patients
• How to access medical cannabis under the current Health Canada process
Presenter Information:
Dr. Paul Daeninck is an oncologist and palliative care consultant with CancerCare Manitoba and is an Assistant Professor at the University of Manitoba. He is the Chair of the Symptom Management and Palliative Care disease site group at CancerCare Manitoba and the President–elect of the Board of Directors of the Canadian Consortium for the Investigation of Cannabinoids (CCIC). He has a research and clinical interest in the use of cannabis and cannabinoids in patients with cancer and cancer-related conditions.
View the video: https://youtu.be/-QFcA4OrqEM
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
This document summarizes a presentation on cannabis in palliative and hospice medicine. It discusses the history of cannabis as medicine, how it works in the body through the endocannabinoid system and cannabinoid receptors, potential medical uses including for pain, nausea, appetite stimulation, and more. It also covers dosing, safety, risks of dependence and withdrawal. Clinical trials show potential benefits for conditions like chemotherapy-induced nausea and vomiting, appetite and weight loss in HIV/AIDS, neuropathic pain, and multiple sclerosis-related incontinence.
Cannabis for pediatric epilepsy pas presentation for distributionPASaskatchewan
This document summarizes presentations by Dr. Richard Huntsman and Dr. Blair Seifert on the use of cannabis for treating pediatric epilepsy. It discusses the objectives of the presentations, which include reviewing epileptic encephalopathies in children, the historical use of cannabis therapies for epilepsy, and contemporary research on cannabis therapies, including the CARE-E study. It also provides an overview of different types of epileptic encephalopathies that affect children, such as infantile spasms and Lennox-Gastaut syndrome. It reviews animal and human studies that have explored the use of cannabidiol and THC in treating epilepsy.
This document presents information on medical marijuana and its potential benefits. It discusses the history of marijuana use, current legality in different parts of the world, components of marijuana like THC and CBD, how marijuana works in the body, potential medical uses to treat conditions like epilepsy, inflammation and chronic pain, limitations and side effects, and arguments for legalizing medical marijuana.
CBD oil may have potential benefits for cancer treatment and prevention. Studies show CBD can reduce cancer cell growth, inhibit tumor development, and relieve symptoms like pain, nausea, and insomnia. However, research is still ongoing into how CBD specifically impacts different types of cancers and what doses may be effective. The endocannabinoid system plays a role in immunity and inflammation, both of which are involved in cancer development, suggesting CBD could lower cancer risk factors. More clinical trials are still needed to fully understand CBD's effects on various cancers.
The document discusses opportunities and challenges for personalized medicines and sickle cell disease treatments. It provides an overview of current limited treatment options for sickle cell disease and highlights several new treatment options currently under development or approval, including Novartis' crizanlizumab, Global Blood Therapeutics' voxelotor, and gene therapies. It notes obstacles to access like high drug costs, long review processes, Canada's drug pricing system, and the small market size. The presentation calls on stakeholders to work together to improve access and education.
The document describes India's 3-tier TB laboratory services system. The peripheral laboratories are located at various primary health centers and hospitals. They provide basic diagnostic services and are covered under quality assurance. State-level intermediate reference laboratories are usually located at State TB Training and Demonstration Centers and monitor laboratory services across the state. They also have CBNAAT and DRTB centers. At the central level are six National Reference Laboratories which provide external quality assurance, drug resistance surveillance, and training.
Adam Williams is a chemistry student from Nantwich, Cheshire who supports Stoke City football club. He completed work experience as a dispenser in a medical center, where he learned about interacting with medical professionals, how centers operate, and properly handling prescriptions. His literature review covered the advantages and disadvantages of medicinal cannabis, finding benefits for pain, nausea, spasms, and seizures, but also respiratory risks, accidents, effects during pregnancy, and psychosis. After university, he is keeping his options open but aims to utilize his experience in the medical industry or with recreational drugs testing at festivals. His 5-year plan involves travel, living abroad, returning to the UK to find work, and potentially starting his
This document discusses the goals and activities of the Adolescent Health and Recovery Treatment Team (AHARTT) program in Kentucky. The goals are to assess and treat adolescent substance abusers and their families using evidence-based practices, and disseminate these treatment models more broadly. It provides funding information from legal settlements and describes treatment models being implemented, including Functional Family Therapy and Cognitive Behavioral Therapy. It also discusses tracking outcomes through the Adolescent Kentucky Treatment Outcome Study and establishing a model clinic to manualize treatments. Key partners and next steps are identified to expand services statewide.
The document discusses various strategies to reduce unnecessary healthcare costs and improve quality, including reducing overuse of procedures, tests, drugs and hospitalizations through evidence-based guidelines and promoting primary care. It notes that higher spending regions do not achieve better health outcomes and that up to 30% of healthcare spending is wasteful.
International Medical Cannabis Policy - Philippe Lucas (Canada) SafeAccess
This document discusses medical cannabis in Canada. It provides background on legal access to medical cannabis in Canada since 2000. It identifies problems with the current federal medical cannabis program, including barriers to access, lack of strain selection, and cost. The document discusses dispensaries as an alternative access model and efforts to regulate them through the Canadian Association of Medical Cannabis Dispensaries. It also outlines proposed changes to Canada's federal medical cannabis program and priorities for medical cannabis research.
Robert C. Randall was the father of the medical marijuana movement. He was the first individual to gain prescriptive access to federal supplies of marijuana for treatment of his glaucoma in 1976. This landmark case established the concept of medical necessity and set legal precedents that paved the way for others to gain access to medical marijuana and the development of state medical marijuana laws. Randall spent his life advocating politically and assisting others to gain legal access to medical marijuana.
More Related Content
Similar to Exciting Developments in Medical Cannabis Movement - Tanya Blasbalg
The document discusses various methods of administering medical cannabis for cancer patients including inhalation, ingestion, and topical application. It notes the time of onset and duration of effects for each method. The document also provides an overview of the endocannabinoid system and how cannabis may help certain cancer symptoms like pain, appetite issues, and nausea. It outlines some promising areas of preclinical research on cannabinoids treating different types of cancer. Potential side effects of cannabis are also mentioned.
Cannabis use is common among those with bipolar disorder. Rates of cannabis abuse are higher among those with bipolar disorder compared to the general population. Cannabis use is associated with increased risk of manic symptoms and can worsen the course of bipolar disorder through increased relapses and hospitalizations. Effective management of comorbid cannabis use and bipolar disorder requires screening, assessment, psychoeducation, and integrated treatment targeting both conditions.
The world is watching as Canada becomes one of the first countries to legalize recreational cannabis, and there's still much we don't know about how this huge social change will affect our lives.
In this webinar, Dr. Chris Wilkes, MD, from UCalgary's Cumming School of Medicine reviews what the research to date tells us about the impact of cannabis on the brain, and what needs further study. Dr. Fiona Clement, PhD, whose team compiled the Cannabis evidence series for the Alberta provincial government, looks at the factors informing government policy, including evidence from other jurisdictions that have legalized marijuana.
Watch the full webinar recording at https://go.ucalgary.ca/2018-07-11URNAP-WhatdoeslegalizedcannabismeanforCanadians_LPRegistration.html
There are countless questions when it comes to medical cannabis and colorectal cancer: How can it help? How do you get it? Are there drug interactions with chemo? What are the side effects? Is it legal where I live?
Cannabidiol (CBD) shows potential as an anti-seizure treatment based on animal studies and anecdotal human reports. CBD appears to reduce seizures independently of CB1 receptors and has a more favorable safety profile than THC in studies. Open-label trials of CBD-enriched cannabis in pediatric epilepsy patients showed reductions in seizure frequency for most participants. However, placebo-controlled studies are still needed to determine CBD's efficacy and safety compared to existing anti-seizure medications.
There are countless questions when it comes to medical cannabis and colorectal cancer: How can it help? How do you get it? Are there drug interactions with chemo? What are the side effects? Is it legal where I live?
The document discusses ongoing debates around the medical use of marijuana. It examines research on marijuana's potential effects on various diseases including cancer, gastrointestinal issues, and mental health conditions. Studies have shown marijuana may help treat cancer by restricting tumor growth and reducing angiogenesis and metastasis. A study on Crohn's disease found patients using marijuana experienced remission of symptoms and improved conditions. However, more research is still needed to fully understand marijuana's medical applications and effects, especially in relation to mental health.
Medical Marijuana and Clinical Oncology in 2022"The Good the Bad and the Potentially Ugly"
Marijuana/cannabinoids are particularly appealing for oncology patients offering the possibility of a single medication to encompass a variety of problems, such as pain, nausea, anorexia, sleep disorders , and anxiety.
Dr. Malcolm Brigden - University of Calgary - Canada.
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
At this webinar you will learn:
• Basic facts about medical cannabis in Canada
• The role of medical cannabis for cancer patients
• How to access medical cannabis under the current Health Canada process
Presenter Information:
Dr. Paul Daeninck is an oncologist and palliative care consultant with CancerCare Manitoba and is an Assistant Professor at the University of Manitoba. He is the Chair of the Symptom Management and Palliative Care disease site group at CancerCare Manitoba and the President–elect of the Board of Directors of the Canadian Consortium for the Investigation of Cannabinoids (CCIC). He has a research and clinical interest in the use of cannabis and cannabinoids in patients with cancer and cancer-related conditions.
View the video: https://youtu.be/-QFcA4OrqEM
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
This document summarizes a presentation on cannabis in palliative and hospice medicine. It discusses the history of cannabis as medicine, how it works in the body through the endocannabinoid system and cannabinoid receptors, potential medical uses including for pain, nausea, appetite stimulation, and more. It also covers dosing, safety, risks of dependence and withdrawal. Clinical trials show potential benefits for conditions like chemotherapy-induced nausea and vomiting, appetite and weight loss in HIV/AIDS, neuropathic pain, and multiple sclerosis-related incontinence.
Cannabis for pediatric epilepsy pas presentation for distributionPASaskatchewan
This document summarizes presentations by Dr. Richard Huntsman and Dr. Blair Seifert on the use of cannabis for treating pediatric epilepsy. It discusses the objectives of the presentations, which include reviewing epileptic encephalopathies in children, the historical use of cannabis therapies for epilepsy, and contemporary research on cannabis therapies, including the CARE-E study. It also provides an overview of different types of epileptic encephalopathies that affect children, such as infantile spasms and Lennox-Gastaut syndrome. It reviews animal and human studies that have explored the use of cannabidiol and THC in treating epilepsy.
This document presents information on medical marijuana and its potential benefits. It discusses the history of marijuana use, current legality in different parts of the world, components of marijuana like THC and CBD, how marijuana works in the body, potential medical uses to treat conditions like epilepsy, inflammation and chronic pain, limitations and side effects, and arguments for legalizing medical marijuana.
CBD oil may have potential benefits for cancer treatment and prevention. Studies show CBD can reduce cancer cell growth, inhibit tumor development, and relieve symptoms like pain, nausea, and insomnia. However, research is still ongoing into how CBD specifically impacts different types of cancers and what doses may be effective. The endocannabinoid system plays a role in immunity and inflammation, both of which are involved in cancer development, suggesting CBD could lower cancer risk factors. More clinical trials are still needed to fully understand CBD's effects on various cancers.
The document discusses opportunities and challenges for personalized medicines and sickle cell disease treatments. It provides an overview of current limited treatment options for sickle cell disease and highlights several new treatment options currently under development or approval, including Novartis' crizanlizumab, Global Blood Therapeutics' voxelotor, and gene therapies. It notes obstacles to access like high drug costs, long review processes, Canada's drug pricing system, and the small market size. The presentation calls on stakeholders to work together to improve access and education.
The document describes India's 3-tier TB laboratory services system. The peripheral laboratories are located at various primary health centers and hospitals. They provide basic diagnostic services and are covered under quality assurance. State-level intermediate reference laboratories are usually located at State TB Training and Demonstration Centers and monitor laboratory services across the state. They also have CBNAAT and DRTB centers. At the central level are six National Reference Laboratories which provide external quality assurance, drug resistance surveillance, and training.
Adam Williams is a chemistry student from Nantwich, Cheshire who supports Stoke City football club. He completed work experience as a dispenser in a medical center, where he learned about interacting with medical professionals, how centers operate, and properly handling prescriptions. His literature review covered the advantages and disadvantages of medicinal cannabis, finding benefits for pain, nausea, spasms, and seizures, but also respiratory risks, accidents, effects during pregnancy, and psychosis. After university, he is keeping his options open but aims to utilize his experience in the medical industry or with recreational drugs testing at festivals. His 5-year plan involves travel, living abroad, returning to the UK to find work, and potentially starting his
This document discusses the goals and activities of the Adolescent Health and Recovery Treatment Team (AHARTT) program in Kentucky. The goals are to assess and treat adolescent substance abusers and their families using evidence-based practices, and disseminate these treatment models more broadly. It provides funding information from legal settlements and describes treatment models being implemented, including Functional Family Therapy and Cognitive Behavioral Therapy. It also discusses tracking outcomes through the Adolescent Kentucky Treatment Outcome Study and establishing a model clinic to manualize treatments. Key partners and next steps are identified to expand services statewide.
The document discusses various strategies to reduce unnecessary healthcare costs and improve quality, including reducing overuse of procedures, tests, drugs and hospitalizations through evidence-based guidelines and promoting primary care. It notes that higher spending regions do not achieve better health outcomes and that up to 30% of healthcare spending is wasteful.
International Medical Cannabis Policy - Philippe Lucas (Canada) SafeAccess
This document discusses medical cannabis in Canada. It provides background on legal access to medical cannabis in Canada since 2000. It identifies problems with the current federal medical cannabis program, including barriers to access, lack of strain selection, and cost. The document discusses dispensaries as an alternative access model and efforts to regulate them through the Canadian Association of Medical Cannabis Dispensaries. It also outlines proposed changes to Canada's federal medical cannabis program and priorities for medical cannabis research.
Robert C. Randall was the father of the medical marijuana movement. He was the first individual to gain prescriptive access to federal supplies of marijuana for treatment of his glaucoma in 1976. This landmark case established the concept of medical necessity and set legal precedents that paved the way for others to gain access to medical marijuana and the development of state medical marijuana laws. Randall spent his life advocating politically and assisting others to gain legal access to medical marijuana.
Medical Cannabis Policy in the US: A History of Resistance - Valerie CorralSafeAccess
The document summarizes the history of the Wo/Men's Alliance for Medical Marijuana (WAMM) in Santa Cruz, California from 1992 to 2013. It outlines key events such as WAMM being formed in 1993 after voters passed Measure A in 1992 to allow medical cannabis use. WAMM played a pivotal role in ensuring cultivation was allowed under Proposition 215 in 1996. It details legal battles between WAMM and the DEA/federal government over the years, culminating in a 10th amendment legal victory for WAMM in federal court in 2008. The document promotes WAMM's websites and social media pages.
1) The document discusses the Dutch model for standardized and quality controlled production of medical cannabis.
2) Key aspects of the Dutch model include cultivation according to Good Agricultural Practices, quality control testing, packaging, distribution through pharmacies, and external auditing.
3) The company Bedrocan produces standardized strains of medical cannabis according to this model, with consistent cannabinoid levels and quality control testing to ensure product safety and reproducibility.
An Integral Frame for MMJ Organizations- Regina NelsonSafeAccess
This document discusses using an integral framework to develop a patient-centered organization for medical cannabis patients. It proposes that such an organization would provide leadership opportunities by empowering patients and cultivating their knowledge and experiences. The organization could help reduce stigma by supporting patients and building community. An integral approach considers both individual and collective needs, and interior and exterior factors, to holistically support patients and advance the discussion of medical cannabis.
History of Medical Cannabis - Dr. Jahan MarcuSafeAccess
The document summarizes research on the role of the endocannabinoid system and cannabinoid receptors CB1 and CB2 in bone formation and density. Studies show that mice lacking both CB1 and CB2 receptors have increased bone mass despite lower osteoblast proliferation. Targeting these receptors in cell studies alters signaling pathways involved in bone growth like ERK, SMAD, and AKT. This suggests cannabinoids influence bone morphogenic signaling and osteoblast function, providing a potential mechanism for the bone phenotype seen in receptor knockout mice. Future work involves using pathway inhibitors and gene expression analysis to further understand these effects.
A History of Medical Cannabis Research and Endocannabinoid System - Dr. Sunil...SafeAccess
This document provides a brief history of medical cannabis research and development. It discusses how cannabis was introduced for medical use in the 1800s in Europe and the US, but became restricted in the 1930s. Some key events and findings include approved cannabis-based medicines in the 1980s, state-sponsored clinical trials in the 1980s showing relief of chemotherapy side effects, and a growing body of research publications and clinical studies since the 1990s despite federal restrictions. The document outlines the increasing acceptance and understanding of medical cannabis through scientific research.
This document provides an introduction to the endocannabinoid system. It reviews the components and role of the endocannabinoid system, including the identification of cannabinoid receptors CB1 and CB2 in the late 1980s and 1990s. It summarizes strategies for harnessing the endocannabinoid system pharmacologically, such as using phytocannabinoids like THC, synthetic cannabinoids, and inhibitors of enzymes that break down endocannabinoids. Novel formulations and therapies aimed at modulating the endocannabinoid system are also discussed.
Science of Medical Cannabis - Michelle SextonSafeAccess
Michelle Sexton is a liaison from the American Society of Pharmacognosy to the American Herbal Pharmacopoeia. She introduced Roy Upton, who studied herbal medicine in the US, Virgin Islands, and China and helped establish standards for herbal supplements. In 2013, the American Herbal Pharmacopoeia published a comprehensive monograph on Cannabis that establishes quality standards and reviews its historical uses, modern research, and safety. The monograph was developed collaboratively and provides a valuable resource for understanding medicinal Cannabis.
Exciting Developments in Medical Cannabis Movement - Tanya Blasbalg
1. Exciting Developments in the
Medical Cannabis Movement:
Continuing Medical Education
Tanya Blasbalg, M.S.
US Medical Education Liaison
Canadian Consortium for the Investigation of Cannabinoids
2. The Need for Cannabinoid Education
MeSH search term: (Cannab*) AND (“xxxx/1/1” : ”xxxx/12/31"[Date - Publication])
Slide courtesy of Dr. Mark Ware
3. The Need for Cannabinoid Education
USMLE Exam Prep Questions
What cannabinoid produces most of the effects of Delta-9-tetrahydrocannabinol
smoking marijuana?
What type of receptor is associated with the 2 G protein-linked receptors
cannabinoid receptor subtypes (CB1 and CB2)?
- Inhibition of adenylyl cyclase opens potassium
channels and closes calcium channels
CB1 receptor location Brain
- Mediate the psychological effects of THC
CB2 receptor location Immune cells
Name the 2 cannabinoid ligands. Anandamide
2-arachidonylglycerol
Marijuana adverse effects (3/4) Increased heart rate
Decreased blood pressure
Reddening of the conjunctiva
Toxic psychosis at high doses
Dronabinol (Marinol) uses (2) Anorexia associated with weight loss in patients
with AIDS
Nausea and vomiting associated with cancer
chemotherapy (second line)
4. Knowledge Transfer:
How HCPs Keep Up With Science
A Perfect World
Self Study Academia Patients
HCP = Health Care Practitioner, ie physicians, nurses, physicians assistants, etc
5. Knowledge Transfer:
How HCPs Keep Up With Science
The Real World: Pharma Sponsorship
Medical Continuing
Promotional
Communications Medical
•
•
Drug Representatives
Journal Ads
•
•
Peer-to-peer programs
Dinner meetings
Education
• Conference booths • Publications • Conferences
• E-detailers • Newsletters • Symposia
• Direct mail • Monographs • Enduring materials
• Brand websites • Advisory boards • Online programming
HCP = Health Care Practitioner, ie physicians, nurses, physicians assistants, etc
6. HCP Resources for Cannabinoid
Education
Slide courtesy of Dr. Jeffrey Hergenrather
7. CCIC: Bringing Credibility to
Cannabinoid Medicine
• Non-profit organization, formed in 2000 as an
interdisciplinary research consortium
• >200 members, primarily clinicians and scientists
• Registered in Canada; global reach &
membership
Mission
To promote evidence‐based education concerning the
endocannabinoid system and therapeutic applications of
cannabinoid agents to clinical audiences
8. CCIC: Providing Accredited
Cannabinoid Education to Clinicians
• >50 live CME programs
– Dinner meetings, workshops, clinical
symposia in Canada, Europe, and the US
• Reached nearly 2000 health care
practitioners
• Feedback overwhelmingly positive
9.
10. The Value of CME
• Accreditation
• Funding firewall
• Unbiased
• Evidence driven
• Clinically relevant to HCPs
11. CCIC: Representing the Diverse
Field of Cannabinoid Therapeutics
Expert Faculty
• Multidisciplinary board of in the fields of:
directors – physicians and Oncology
scientists Pain management
• Collaborations with HIV/AIDS
professional societies and Neurology
academic institutions Multiple Sclerosis
• Management staff with Pulmonology
experience in medicine, Psychology
science, business, and Pharmacology
education Family Medicine
Anesthesiology
13. Challenge: Getting HCPs in the Room
HCP Objections
• There is no data
• Cannabis must be smoked
– “I would never tell my patient to smoke
something”
• Cannabis = THC
– “They can just take Marinol”
• Cannabis gets you high
• I have no intention to recommend, therefore
this doesn’t affect me
• I can get arrested for recommending
cannabis
14. Challenge:
The Art & Science of Medicine
• The folly of evidence-based medicine
Effective patient care requires the free and unfettered
exchange of information on treatment alternatives…
- American Medical Association
American Medical Association. AMA Policy: Medical Marijuana. Report 10 of the Council on Scientific Affairs.
Available at http://medicalmarijuana.procon.org/sourcefiles/AMA09policy.pdf. Accessed 23 Feb 2013.
15. Limitless Opportunities
• Live meetings (half day, full day)
• Online CME
• Grand rounds presentations (hospitals)
• Medical school cannabinoid curriculum
• Patient education materials
• Risk evaluation and mitigation strategies
• And on…and on…and on…
16. The Canadian Consortium for the
Investigation of Cannabinoids
www.ccic.net
Tanya Blasbalg
US Medical Education Liaison
tanya@ccic.net
Editor's Notes
This is an issue you’ve been hearing about during the conference. I’m here to discuss a solution
2036 Cannabinoid science is lagging behind other medical sciences Lipid chemistry took longer to develop than hydrochemistry The endocannabinoid system is harder to study than other physiological systems
USMLE 1/3 of HCPs live in states with medical marijuana laws. Arguably, none of them learned how to administer cannabis in medical school http://quizlet.com/12565059/psychiatry-pharmacology-usmle-flash-cards/
We’d like to think that this is how all our HCPs learn everything
But this is the truth of it Mainstream, speak their language, my role and expertise Accreditation Requirements for CME Providers Requirements for Recognized Accreditors Enduring Materials: Definition and Requirements Because there is no direct interaction between the provider and/or faculty and the learner, the provider must communicate the following information to participants so that they are aware of this information prior to starting the educational activity Principal faculty and their credentials; Medium or combination of media used; Method of physician participation in the learning process; Estimated time to complete the educational activity (same as number of designated credit hours); Dates of original release and most recent review or update; and Termination date (date after which enduring material is no longer certified for credit). Providers that produce enduring materials must review each enduring material at least once every three years or more frequently if indicated by new scientific developments. So, while providers can review and re-release an enduring material every three years (or more frequently), the enduring material cannot be offered as an accredited activity for more than three years without some review on the part of the provider to ensure that the content is still up-to-date and accurate. That review date must be included on the enduring material, along with the original release date and a termination date. Sometimes providers will create an enduring material from a live CME activity. When this occurs, ACCME considers the provider to have created two separate activities – one live activity and one enduring material activity. Both activities must comply with all ACCME requirements, and the enduring material activity must comply additionally with all ACCME policies that relate specifically to enduring materials. ACCME Note: This policy describes ACCME requirements with regard to the ACCME-defined activity type, enduring materials. The ACCME defines enduring materials as CME activities that are printed, recorded, or accessible online and do not have a specific time or location designated for participation. Rather, the participant determines where and when to complete the activity. Examples: online interactive educational module, recorded presentation, podcast.
Local resources developing in different areas
DOH, exec director of medical society 35 cannabis-niaive physicians
Accreditation = motivation
State governments ar our natural partners
Nice thing about HCPs is they are often open to sound, rational perspectives supported by data. I’ve come out of the closet What I have been finding is that HCPs sometimes think they have an informed opinion, and those opinions keep them from getting in the door to hear the evidence Smoked cannabis causes lung disease and cancer Euphoria is an adverse side effect
Despite all the data, at the end of the day every physician must rely on their own clinical judgment for their treatment decision. That judgment is formed by weighing not only the scientific evidence, but also personal clinical experience and guidance from colleagues. For some reason, to many physicians the art of medicine doesn’t apply when in comes to cannabis.
When pharma has a problem, you better believe we put our heads together and come up with unique, creative solutions, and lots of them. There is no reason we can’t do the same for cannabis.